Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2021 Seres Therapeutics, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions] It’s now my pleasure to introduce, Dr. Carlo Tanzi, of Investor Relations.

Thank you and good morning. Our press release with the company’s fourth quarter 2021 financial results and a business update became available at 7.00 AM Eastern Time this morning, it can be found on the new Investors and News sections of the company’s website. I would like to remind you that we will be making forward-looking statements related to the timing, enrollment, and results of our clinical studies. The anticipated safety profile of our products, the timing of potential regulatory approval SER-109, the success of our agreement with Nestlé Health Science, the anticipated market for SER-109, and the promise and potential impact of any of our microbiome therapeutics. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the Risk Factor section of our recent SEC filings. Any forward-looking statements made on today’s call represent our views as of today only. We may update these statements in the future but we disclaim any obligation to do so. On today’s call with prepared remarks, I am joined by Eric Shaff, President and Chief Executive Officer; Dr. Lisa von Moltke, Chief Medical Officer; Dr. Matthew Henn, Chief Scientific Officer; and David Arkowitz, Chief Financial Officer. During the Q&A portion of the call, we will also be joined by Dr. Terri Young, Chief Commercial and Strategy Officer; and Dr. David Ege, Chief Technology Officer. With that, I’ll pass the call to Eric.

Thank you, Carlo, and good morning, everyone. 2021 was a very productive year for Seres, where we have made meaningful advancements in our microbiome therapeutics pipeline. At the center of this progress was our lead SER-109 program and our momentum towards and expected BLA filing in the middle of this year. The significance of SER-109 and our successful pivotal clinical data in recurrent C. difficile infection was recently highlighted by the publication of the Phase 3 study in the New England Journal of Medicine. We believe that SER-109 has the potential to become the first ever FDA approved microbiome therapeutic, a landmark for this emerging class of medicines. Pending SER-109 FDA approval, we believe we have the opportunity to transform the treatments of recurrent C. diff infection. To remind you of our SER-109 efficacy results, our Phase 3 data demonstrated a significant reduction in the proportion of recurrent C. diff patients experiencing the further recurrence demonstrating superiority versus antibiotics alone. Furthermore, the Phase 3 data surpassed statistical thresholds that have been communicated to us by the FDA that could allow the single clinical study to fulfill efficacy recruitments for BLA. The FDA had also communicated that our BLA filing should include a safety database of at least 300 subjects receiving the Phase 3 dose, and with a 24-week follow up. Our SER-109 open-label study is fully enrolled, and we continue to gather the required safety data. Notably, the SER-109 open-label study also includes individuals with a first recurrence of C. diff infection and expansion compared to the Phase 3 study population, which included only those with multiple recurrent CDI. The combination of first recurrent and multiply recurrent patients across our studies represents a broad segment of patients living with recurrent CDI. As we prepare for a SER-109 BLA filing, we…

Thanks, Eric. Since obtaining the initial SER-109 top-line results in July of 2020. We have presented various datasets at a number of prominent conferences attended by infectious disease physicians and gastroenterologists. Well, we certainly in January, we were very pleased to have published the complete Phase 3 study results in the New England Journal of Medicine. The publication highlights study results that demonstrated SER-109 to be superior to placebo and reducing CDI recurrence, with 88% of SER-109 patients achieving a sustained clinical response compared to 60% on placebo. This was a highly statistically significant difference. In this study, SER-109 was also observed to be well tolerated, with a side effect profile, comparable to placebo, and no serious drug related adverse events observed. The New England Journal publication has had the benefit of increasing physician awareness and interest in SER-109. As a result of the publication, we have seen a marked increase in the number of inbound inquiries we’ve received about the program, and we believe that there is a high level of physician interest in incorporating SER-109 pending FDA approval into their clinical practice. In addition to demonstrating the opportunity for microbiome therapeutics to impact recurrent CDI, we believe that our SER-109 data have also provided clear clinical and mechanistic evidence supporting microbiome therapeutics potential impact on infection protection more broadly. The gastrointestinal tract is known to have an important role in preventing pathogen infection, including from life threatening pathogens that can harbor antibiotic-resistant, increasing emergence of antibiotic-resistant has become a significant public health threat, a new non-antibiotic treatment approaches are desperately needed. Our SER-109 data demonstrates that microbiome therapeutics can result in significant restructuring of the gut microbiome and that these changes can lead to significant reductions in pathogenic bacteria, including those associated with antibiotic-resistant. We believe that there…

Thank you, Lisa. As we highlighted in detail during our January 31st investor event, we believe that both our clinical and preclinical data provides strong evidence to supporting the potential for microbiome therapeutic in Infection Protection. We see the potential to reduce the abundance of targeted pathogens to decrease the potential for pathogen transmission, strengthen epithelial barriers to further reduce the frequency of bloodstream infections, and to modulate immune responses to tackle medical complications, such as graft versus host disease. Seres has developed an integrated platform that has enabled the discovery of novel therapeutic candidates designed to protect patients from infections. We are building on the success of SER-109 with SER-155, we’ve also initiated additional preclinical programs targeting Infection Protection. These include evaluating opportunities and patients receiving autologous HSCT and designing consortia to deploy in settings such as cancer neutropenia and solid organ transplant, as well as combating the slow pandemic of antimicrobial-resistant infection more broadly. We are driving towards initiating and additional clinical development program in 2023 are progressing additional programs into the clinic over the next few years. Now, moving to our ulcerative colitis efforts. UC is an area of strategic interest for Seres and we believe it is a disease that may be particularly well suited for microbiome intervention. I’ll begin with a recap of our efforts targeting UC and some prior datasets. Last summer, we announced top-line results from our Phase 2 ECO-RESET study evaluating SER-287, a donor-derived investigational microbiome therapeutic candidate, in patients with mild-to-moderate ulcerative colitis. Our both dosing regimens of SER-287 were generally well tolerated. The study did not meet its primary endpoint of improving clinical remission rates compared to placebo. Late last year, we announced additional microbiome drug pharmacology data from the Phase 2 study that indicated that the engraftment of SER-287…

Thanks, Matt. The details of our full year and quarterly financials are included in this morning’s press release, so I won’t reiterate all the figures here. Seres ended the fourth quarter of 2021 with approximately $291 million in cash, cash equivalents and marketable securities. We are pleased to announce today that we have amended our debt financing agreement with Hercules Capital, providing the company with a debt facility of up to $100 million. This debt financing is a term loan, which we drew down $50 million upon closing last week. This amendment replaces our prior $50 million debt facility with Hercules and approximately $22 million of the proceeds we received last week under the amended agreement will pay-off the remaining amount owed. With respect to our operating expenses and efforts over the near-term, we continue to be focused on a number of critical SER-109 related activities, which include preparing and filing the BLA submission, continuing to ramp-up manufacturing operations for commercial supply, including increasing longer term SER-109 product supply to our Bacthera collaboration and in conjunction with Nestlé, continuing and accelerating launch readiness activities. In addition, we continue to invest to advance and expand our pipeline with a focus on Infection Protection opportunities, and further build upon and enhance our platforms and capabilities. As a result of these high priority and value generating activities, we expect our expenses to increase in the coming quarters, but at a moderating rate of growth, as we have already expanded our capabilities across much of the organization. In summary, we believe the company is well resourced to prepare for SER-109 commercialization drive our ongoing development and preclinical programs, while also deploying resources to continue to advance our research platforms, where we believe we have differentiated, proprietary and sustainable advantages. I’ll now pass the call back to Eric.

Thanks, David. I will conclude our remarks by recapping key 2021 progress milestones as well as upcoming anticipated value drivers for the year ahead. These include achieving target enrollment in our SER-109 open-label study and our preparation for our BLA filing in the middle of 2022. Can you progress executing on SER-109 pre-commercial readiness, working closely with Nestlé Health Science, Aimmune, including expanded market education efforts. The initiation and ongoing execution of our SER-109 expanded access program. The expansion of our longer-term commercial supply capabilities, including our collaboration with Bacthera; continued data analysis to inform future development in ulcerative colitis; SER-155 study initiation and ongoing execution and expansion of our efforts targeting in Infection Protection, an area of incredible opportunity to serve patients, which directly builds upon the success of SER-109. We also continue to strengthen our microbiome research platform and preclinical efforts. In 2022, we expect to advance new microbiome therapeutic candidates towards clinical developments, particularly in Infection Protection, where we believe we have clear clinical and mechanistic data supporting our approach. Seres is well positioned to lead the microbiome therapeutic field, and we intend to continue to execute on our mission, working hard to improve the lives of patients. With that now, operator, we’ll open the call up to questions.

[Operator Instructions] Our first question comes from the line of Mark Breidenbach with Oppenheimer.

Hi, good morning. This is Jacquelyn [ph] on for Mark, and thanks for taking our questions. My first question is how is the baseline metabolic profile being defined in SER-301 study acceptor? How many individual biomarkers are used in this characterization? Thank you.

Good morning, and thanks for the question. Matt, do you want to take that one?

Sure. We’ve been looking at a whole suite of disease-relevant metabolic biomarkers in our UC patients that we had predefined to be important. And in addition to that, we have been looking at in discovering novel biomarkers that we believe are important in relevance for disease based on the datasets that basically we’ve generated. We haven’t spoken, disclose yet the specifics of the number of biomarkers, but what I can tell you is that we have identified a few biomarkers that are consistent, and that we believe could be used potentially for patient stratification [into Seres] [ph].

Okay, that’s good to know. Thanks. And also, do you plan to modify or compensation of SER-301 based on observations from the first site 15 patients?

Yeah, so all of our data to-date support that the pharmacological properties of SER-301 are consistent with their design, and that the drug is exhibiting pharmacological properties as it was designed to do. So at this time, we do not anticipate any changes to the consortium.

Okay. So my next question is regarding SER-287. So based on the biomarker profiling, what fraction of mild-to-moderate UC patients, do you think could be good candidates for – of 287 and 301? And also, is there any difference in the biomarker defined populations, you’re considering for continued development of both molecules?

Matt, do you want to start with that one? And I’ll close some comments on that.

Sure, yeah. So we do think that the patient subpopulations that we’ve identified still represent a significant portion of patients with ulcerative colitis. So those that we have identified to be most receptive are somewhere on the order of about 30% to 40% of the patients in the population. We haven’t provided any details further than that at this time.

Yeah, I might just add a larger comment. We are learning, iterating, and I think it’s worth noting that we have a significant amount of data here with the 287 study results, both clinical and microbiome. Now the first 15 subjects of the 301 study, we will continue to learn and adjust from the study results, and we’ll follow the data, and I think it’s worth noting. If you think back maybe to the 109 experience after the Phase 2 study results, we had a lot of confidence in the underlying thesis and a lot of data to support it. But we didn’t just say, look, let’s run another study and hope that it kind of ends up clinically, where we’d like it to. We made a number of adjustments based on data, turns out that those adjustments led us to a very positive spot. And that certainly is the process that we have intended to take with our efforts in IBD and UC, and that’s what we’re doing now.

Great, thanks. That’s really helpful. That’s it for me. Thanks again for taking our questions.

Thanks for the questions.

Thank you. And our next question comes from the line of Ted Tenthoff with Piper Sandler.

Great. Thank you guys. So really exciting point for the company. I’m just trying to get a better sense as you prep for the BLA, obviously, a very strong data set here. And will you be reporting or presenting the safety data? Or will that be something that simply goes into the BLA? And then also, if I may, with respect to the relationship with Nestlé, how are you guys working to kind of prep for launch together? Thanks so much.

Yeah, Ted, good morning, and thanks for the questions. Maybe I’ll ask Lisa to start with the second. And I’ll ask Terri to hit the – I’m sorry, Lisa, to start with the first one, and Terry, to start with the second one. On the first, maybe I’ll just start by commenting that, we are still in the process of following these patients out. But maybe, Lisa, you can comment further on the open-label study and how we’ll track it.

Yeah, so we haven’t said yet, how we’ll make those data public and how to communicate. But I will say that we are eyeing our possibilities in terms of conferences and other ways to disclose as soon as we have that dataset finalized.

And then, Terri, can you just comment on our work with Nestlé Health Science and some of the pre-commercial work that we have conducted together?

Sure thing. Well, I guess, I’d start by highlighting that, we ramped these efforts upon receipt of the data, right, at the Phase 3 data, remarkable data that we had, and then yet again with Nestlé after signing the co-commercialization agreement last year. So we’ve now integrated the team at Nestlé into our efforts. And we’ve worked together to scale both our market education, but also our data dissemination efforts. And these are primarily being led in the medical affairs to Lisa’s team, and I’ll ask her to – I’ll hand it back to her in a minute to comment on that, but also in our market access team. For example, we’re developing a robust payer value proposition that is supported by the really strong category leading profile with SER-109, but also the high cost of treating recurrence that Eric highlighted in his remarks today. And, this is treating recurrence after recurrence in these patients, and the options today are quite limited. And Nestlé has an existing payer field team to engage this important audience. And we’ll be doing that pre-launch in accordance with existing FDA guidance on pre-approval information exchange. So that’s a pretty big book of work on the payer front and value proposition front. We also continue to work with them to deepen our understanding of the market opportunity and we’re progressing items like brand positioning efforts, HCP, payer and patient segmentation and branded campaign development. And finally, last year, we launched a broad disease education campaign at ID, we can will be amplifying that campaign as we move throughout 2022. Finally, we’re continuing to hire industry leading commercial talent into both of our organizations. Now, I’d like to ask, Lisa, specifically to comment on the medical affairs activities in front particularly in light of the recent publication of the pivotal data in New England Journal of Medicine.

Yes, thanks, Terri. Yeah, so the med affairs efforts really are spanning a number of areas that you’d expect including publications. The New England Journal was incredibly impactful with regard to the reception in the physician community, and we’ve already heard of infectious disease, physicians bringing this up on rounds, and in their discussions with their colleagues. But the Nestlé group is an Aimmune group, are fully integrated as we move through planning further publications, mobilizing the MSLs, they’re out there on the ground, talking to physicians. There are lots of education activities that are going to be culminating and seeing new programs, and we’re also working with the patient advocacy groups. And we’re very pleased with how the Nestlé Aimmune team is blending in and being part of that effort.

Very, very helpful, very thorough and I appreciate it everybody.

Thanks for the questions, Ted.

Thank you. And our next question comes from the line of Peyton Bohnsack with Cowen.

Hey, good morning, guys. And thanks for taking our questions. I’m on for Joe. So just a real quick question about the expanded access program in the U.S. I was wondering how many patients have been treated through this end program? How the demand has been? And whether you can share any details about whether this has been mostly first recurrence or multiple recurrence patients? Thank you.

Yeah, Peyton, I would say, we’re just getting started with the expanded access, just having at the end of the year included the open-label 300 patient, but we had been targeting. But, Lisa, can you cover for that?

Yeah, we haven’t really given specifics, I can tell you that it’s up and running. We have patients enrolled. We have numerous sites across the company, we’ve tried to strategically place them so that we’re – we patients can access the site, regardless of where they are. And we look forward to giving you more information in the future. But we haven’t really been specific on numbers yet.

Thank you. That’s really helpful. And then maybe a real quick question the SER-155 program. I know that when this was talked about previously, it said that the cohorts you could begin enrolling before cohort 1 finishes. Is there a certain level of efficacy that would be required to begin enrolling cohort 2, and then also – are there any plans to expand the number of sites with this trial was being conducted? Or is it just going to be at the Chicago and MSK sites? Thanks.

Lisa, maybe you can comment on both. I think, one is the protocol structure and progression. And the other is maybe the last in terms of sites.

Yes. We’re at 2 sites right now, and we were intending to increase those. So I think what you’re referring to with the first part of your question is that there is a pretty long safety follow-up over the cost of X over an entire year. We don’t need to wait for that entire year to start the second cohort. The first has to finish the first set of patients through an initial safety assessment. And at that point, we’re free to go into the second sector without waiting that entire year of safety follow up. I think that’s what you’re probably referring to.

That’s exactly. All right. Thank you so much.

Sure.

Thanks for the questions.

Thank you. And our next question comes from the line of Chris Shibutani with Goldman Sachs.

Hi, this is Steven on for Chris. Thank you for taking our question. I had one on the 301 program. Do you expect that your label would include language or how many recurrences a patient must have prior to going on 301? And then just if you could comment on [after] [ph] that you’re seeing these patients with first recurrence versus kind of the Phase 3 trial population? Thank you.

Steven, I want to make sure that we’ve got our numbers or programs, right, with the question was 301 around recurrences. Do you mean 109?

Oh, yeah. Sorry about that.

Okay. All right. No problem. Yeah. So look I think what we said before is that the label, of course, will be part of the negotiation that will happen with the FDA as part of the BLA process. We don’t want to get ahead of that. At the same time, we absolutely think that medically, and Lisa, pass and certainly can again speak to our view of why we think that recurrent C. diff patients is [that in line] is appropriate for that patient population. And maybe, Lisa, let me handed to you on that.

Yeah, I think both from a pathophysiology basis as well as how our interactions with physicians are indicating they think about recurrent disease, it’s pretty much falls into primary disease, primary recurrent and everything else. And from pathophysiology standpoint, that first recurrence is the marker and happens, because the microbiome is unable to suppress the germination of those spores. And that’s the point that we’re at which it makes sense to start restructuring. And as well physicians in practice tend to see a C. diff infection as either my first bout or everything else. So for those reasons, we really see this as an appropriate therapy, but as for all recurrent patients. But as Eric said, the label will reflect the negotiations with the agency.

And maybe just the follow, I think you had asked about the percentage of first recurrence that we’ve seen in the open-label, and we haven’t disclosed that data. But as Lisa mentioned, we’re kind of have our eyes on opportunities once we’re past the follow-up period to disclose those data.

Got it. Thank you for taking our questions.

Sure. Thanks for the question.

Thank you. And our next question comes from the line of John Newman with Canaccord.

Hi, there team. Good morning, and thanks for taking my question. So the question about the SER-301 data. I noticed in your press release as well as in your prepared remarks, you mentioned that SER-301 did modulate short chain and medium chain fatty acids, which interesting is many patients actually will take those types of products, sort of off label. But just curious if those types of changes were relatively consistent across the patients in that first cohort. You did mention that based on metabolic state affected the changes in parted by 301. But just curious, specifically on the short to medium chain fatty acids, if that was somewhat consistent across the patients that you looked at? Thanks.

Yeah. John, good morning, and thank you for the question. I’m going to hand it to Matt. But I’ll do so just with the first qualification that you have to remember we’re talking about 15 subjects, right? So it’s a pretty limited data set. And that said, it’s interesting, and we think we’re going to learn quite a bit from it. And we are in the process of analyzing some of the datasets have come from it. But maybe – I’m going to hand it to Matt.

So a couple of – good morning, John. A couple of points. So first, as I started with ulcerative colitis was 15 subjects in 301. So we need to be cautious in terms of the extrapolation of those results. But I think it’s clear that SER-301 certainly demonstrate at the pharmacological properties that it was designed to exhibit. And certainly short-chain fatty acids and medium-chain fatty acids are one particular metabolite that their SER-301 is designed and optimized to produce, there are multiple others as well. And these UC patients are certainly a heterogeneous patient population, and you certainly can see variations in the short-chain and medium-chain fatty acids amongst patients at baseline. I will tell you that that is not the biomarker that we are focused on with respect to our patients, and in the population that we’ve identified. But that is certainly an important functional parameter that we continue to assess and evaluate, and know that modulating that can be one important mechanism in the context of reducing inflammation in the gastrointestinal tract. There are multiple others as well, that we are focused on. The second part of your question is – and just a comment on – another part of your question, which is a comment that you made us folks taking these sort of compounds, if you will, off label, what’s important is that, I think what’s important about our drugs is that it’s the bacteria that are producing these and while you have not seen success with patients previously taking things like bile acids or short-chain fatty acids, or other metabolites, to vitamins, et cetera, because of course, these things need to get to the site of activity and where they need to be. And I think that’s one of the clear benefits of our technology is that we’re using the bacteria as drugs and the bacteria naturally and have evolved to be at the site where it’s most relevant to have those effects. So the bacteria producing the metabolites at the site that we want them to.

Okay, great. Thank you.

Thanks for the question, John.

And our next question comes from the line of Gobind Singh with JMP Securities.

Hey, thanks for taking my questions and congrats on the progress. I could dig a little bit more into the 301. Is it possible and would it be accurate to say that the positive metabolic changes, I think, the 301 were meaningful compared to the changes that we’re seeing with 287 or the lack thereof. And since we’re talking about metabolic profile, just wanted to confirm that the engraftment profile with 301 was presumably robust, and I don’t know if there’s any way to talk about the quantitative difference if there was any compared to 287, and how that could maybe tend towards dependent metabolic changes that you guys are now seeing? This would be a positive indicator. And if there’s any feedback or comments that you could share around our metabolic profile and for the baseline or otherwise, and optimizing that could contend towards clinical remission, maybe on a general level or just from data out there, I know there’s only 15 patients here. That would be great. Thank you.

Yeah, Gobind, good morning, and thank you for the questions. There’s a lot there in terms of – in your questions around some of the depths of our microbiome analysis. And I – again, I’m going to pass it the map, but I’ll do so with just the caution that we are – we continue to be in the process of analyzing this data. We are striving to put ourselves in the best position to help patients and, of course, return to – have a return for shareholders, based on our efforts in UC. And we are iterating and we’re learning and there’s a number of datasets that we think put ourselves in the position to have more visibility perhaps than others as it relates to maximize our chance of success in UC. But there’s a lot for us to do, and maybe Matt can take it there forward.

Yeah, Gobind, I think I heard 2 questions in your comments. So one was a question about the engraftment of SER-301 bacteria in patients post-treatment; and the second was the magnitude of metabolic changes in the SER-301 cohort 1 population versus SER-287 population. So with respect to engraftment, yes, we did see both rapid and durable engraftment of SER-301 bacteria into patients post-treatment. You may recall that, one reason, we had this first cohort was that we were testing a novel formulation of the drug where we had bacteria in the drug formulated both in the form of spores, as well as in the form of vegetative bacteria. And we wanted to evaluate that formulation in the cohort 1 study, and I can tell you that we saw both the engraftment of spore formulated bacteria as well as vegetatively formulated bacteria, which I think is important because it speaks to the strength and the breadth of our manufacturing capabilities at the company – excuse me, engraftment, as we have consistently observed across our studies can have variability from patient to patient. But we certainly consistently get bacteria on board. And importantly, what we have sort of shifting to the second question you had the magnitude of metabolic changes, we certainly were able to observe trends and changes and as well as significant differences in multiple predefined metabolites that we think are important and relevant for the treatment of UC, and for which SER-301 is designed to do. In terms of the magnitude of that, as we noted in the Phase 2 study as SER-287, we did not observe these predefined metabolic changes that we had anticipated to and that was a surprise, whereas in the context of SER-301 we did and a good number of those were also significantly changed at multiple different time points in the course of the study. So we saw more meaningful changes in the context of SER-301.

Yeah, so Gobind, maybe I’ll just close by saying, we will continue to think about as you often do with a Phase 1 study, optimizing dose continuing to analyze the biomarker data that we think is intriguing, and especially given the heterogeneous disease like UC thinking about patient segmentation where we can have an impact on the right patient group. So those are the pieces that we are currently continuing to iterate on.

I appreciate you guys making advancements [in the site] [ph].

Thanks for the question.

Thank you. And our next question comes from the line of Vernon Bernardino with H.C. Wainwright.

Hi, everyone. Thanks for taking my questions and congrats on the process looking forward to the BLA mid-year. So with SER-109, the results show the highest state clinical response rate about 88% yet in a survey you conducted. There’s still a significant number a percentage rather of prescribers, who definitely might not prescribe SER-109. What is the driver of their hesitancy? And what kind of efforts do you think during commercialization? Do you think you could implement to perhaps target that perhaps significant patient population that may not receive SER-109?

Very good morning, and thanks for the question. I’m going to ask Terri to comment. But I would say that the conclusion based on the question is, we have a very different point of view from what [you bought the size] [ph] based on the analysis that we did, in fact, we felt extremely favorable in terms of what we heard back from our primary research. But Terri, maybe you can take that one forward.

Yeah, thanks, Eric. I mean, it’s a great question. And I would refer you to a slide that is in our current corporate deck that actually illustrates feedback that we’ve obtained recently from both HCP and payers. And what you’ll see as if you’d look at the HCP response, it’s actually quite remarkable in the positive direction, we have a – what I would call a sea of green. And this is likelihood to prescribe data, right? So the vast majority of physicians saying that they are probably or definitely will use SER-109 within their patient population, and for something that’s transformative, and such a new approach to care like SER-109, that’s actually quite unusual. So I imagine your question is more in the smaller gray percentage that are sort of labeled…

Exactly.

Yeah, as a might or might not. So this is actually very typical again in the new category. You get what I call the fence-sitter [ph]. So they tend to – you’re showing them a profiling research, right? And you’re asking them based on one piece of paper, would you use this in your patient population, and they’re just a more cautious physician set. So they want to, for example, hear from their specialist down the street, they want to wait for FDA approval, they want to understand the data and a little bit more depth. So these fence-sitters don’t tend to sit for very long. But that’s typically the dynamic that you’re dealing with. So how do you deal with it, then it’s through the approaches we’re taking today around market education from the medical affair standpoint. And, of course, that approval, we can deploy our broader field force as well, publications, conferences, and of course, the BLA approval.

I’m sorry, I implied – I do realize there’s a [C agreement] [ph] I’m sorry, I implied, then there was has a greater hesitancy seems like that’d be a low bar. I’m sorry, Eric, go ahead.

No, no, I was going to say, I appreciate the clarification. And, I would just say, we feel we’re starting commercially from a very good spot based on the data, it really comes down to the data more than anything else, right? And we couldn’t be more pleased with the dataset that we have. We think it resonated, as we’ve talked about in the past, in the momentum that we saw as the open-label study was conducted, even amidst the pandemic. We saw with the acceptance of the manuscript into the New England Journal of Medicine. Lisa has commented earlier and can maybe comment again just in terms of the med affairs side, which we think is really important work that we have to do with our partners and ensuring that that people know about this technology, they know about this profile. And maybe Lisa you can comment.

Yeah. No, I think I can’t overstate really the impact from the New England Journal paper in really solidifying the position of the data for so many of the physicians, I think, not only within folks who have been watching and wanted to see the whole dataset, I think I can also say that we’ve heard from people who were still somewhat skeptical and still hanging on to FMT, or other potential alternatives, who’ve now contacted us and said, now that I’ve seen that dataset in a peer-reviewed. In this particular peer-reviewed journal and I’ve seen the data for myself, I really am just blown away, and I can’t wait to be able to use it. So I think we’re well positioned to be able to do the education that we need to do.

I guess, you are in. And thanks for taking my question and looks like the publication the New England Journal of Medicine is going to help with the fence-sitters. Thank you and congrats on the progress.

Thanks for the question, Vernon.

Thank you. I’m showing no further questions. So with that, I’ll turn the call back over to management for any further remarks.

So thank you and I want to thank everyone for joining our call today for your continued interest in the Seres. We look forward to keeping you updated on our progress and with that will conclude, I hope everyone has a great day. Thanks very much.

Ladies and gentlemen, this concludes today’s conference call. Thank you for participating and you may now disconnect.